
Company Location

1435 North Hayden Road
Scottsdale, Arizona 85257

Contact Numbers

Tel 1: (480) 970-4970
Tel 2: (877) 970-4970
Fax: (480) 970-8792

Contact

Mary Ritz
ritz@regenesisbiomedical.com

Overview

Provant is a safe, non-invasive technology that promotes faster healing at a lower cost. Our unique patented biotechnology has been cleared by the FDA for key indications in U.S. wound care market. Patients, physicians and nurses all find Provant effective and easy to use, while administrators appreciate the Company's emphasis on cost-effective positive outcomes.

Several important factors have created a strong need for wound treatments that work and reduce healthcare costs. One key factor is a rapidly expanding aging population. Another factor is the continued drive to curb escalating medical care costs both in the public and private sectors. When one considers the fact that traditionally there have been few effective wound treatment products, it is clear that a significant opportunity exists for a company like Regenesis to make a large impact in the area of wound care.

Our products are in use in many of the leading healthcare systems and organizations in the United States, including the Veteran's Health Administration, Baylor Specialty Hospital, and Centennial Healthcare. Our customers include health care facilities and providers that serve patients with problem wounds: acute care hospitals, long-term acute care hospitals, skilled nursing facilities, residential nursing homes, home-health care agencies, and outpatient wound care clinics where physicians, nurse practitioners, and physical therapists can prescribe Provant treatment.

Regenesis Biomedical, Inc. was founded in 1997 as a Delaware C corporation. The Company is headquartered in Scottsdale, AZ. Management consists of proven leaders in business and the life sciences.

Regenesis is growing rapidly based upon the success of its market focus and approach to business. The Company's products offer a unique combination of advantages unmatched by other products, including: an approach to treatment driven by an understanding of wound repair biology, effectiveness backed by strong clinical trials, lower cost per patient per day, non-invasive treatments, and ease of use. Plus, Regenesis backs its' products with warranties and a commitment to service second to none.

Research

For the past several years, wound healing strategies have typically attempted to augment growth factor concentrations at the surface of a wound. While initial acceleration of healing has been shown, time to full wound closure has not decreased substantially. Alternatively, the development of the Provant® Wound Closure System, based upon Cell Proliferation Induction® (CPI®) biotechnology, represents a breakthrough in our ability to signal multiple growth factors and genes and initiate a full wound repair sequence.

The CPI signal affects the expression of several hundred genes known to be involved in wound repair and tissue regeneration. From inflammation responses to tissue regrowth to scar remodeling, all of these are induced by the CPI signal. As a result, CPI causes the synthesis of over eighty growth factors and receptors, and robustly recruits cells into the cell division cycle.